Publications

Objectives

We investigated whether androgen deprivation therapy use in prostate cancer patients is associated with decreased risks for second primary lung cancer in the US veterans.

Methods

Prostate cancer diagnoses among the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Use of hormonal therapy and diagnoses of second primary lung cancer were determined from the registry. Synchronous prostate and lung cancers, defined as two diagnoses made within 1 year were excluded from the analysis. Cancer free survival was estimated with Kaplan-Meier method and hazard ratios were estimated with Cox proportional hazard model.

Results

Among the 63,141 patients with prostate cancer identified, 18,707 subjects were eligible for the study. Hormonal therapy was used in 38% of patients and median follow-up period was 28 months. ADT use was associated with longer lung cancer free survival in prostate cancer patients (logrank p=0.01). After adjusting for age, race, smoking and prostate cancer stage, ADT use was associated with decreased lung cancer risk by 15%, 21%, and 24% after 1, 2, and 3 years, respectively.

Conclusion

Androgen deprivation therapy in prostate cancer patients is potentially associated with decreased second primary lung cancer risk among the US veterans.